IRCT20100119003106N47招募中Unknown
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Assessment of the Effects of Postbiotic Supplementation with Lactobacillus rhamnosus CRL 1505 and Lactobacillus acidophilus (Johnsonii) La1, with a Focus on Interferon-Gamma; Impact on Upper Respiratory Tract Infection Incidence
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •Adult men and women aged between 18 and 65 years who enter the study must have a thorough comprehension of the potential risks and benefits.
- •They are required to sign informed consent forms before participating.
排除标准
- •Reluctance to continue or participate in the study
- •As diagnosed with decreased immunity due to any chronic illness
- •Gastrointestinal ulcers, liver and kidney dysfunction
- •HIV (Human Immunodeficiency Virus), autoimmune disorders, malignancies, or any history of malignancy
- •Diagnosed respiratory illnesses with symptoms resembling cold or influenza
- •Severe conditions such as asthma and severe allergies
- •Pregnancy, breastfeeding
- •Substance abuse or alcohol addiction
- •Use of any immune-suppressing or immune-modulating agents
- •Patients with known allergic reactions to intervention drugs
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectioCrohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000886-19-ATMillennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)96
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer PaiEUCTR2005-001725-28-ATGlaxoSmithKline R & D Limited750
进行中（未招募）
1 期
A Phase 2b study to demonstrate the safety and efficacy of Tildrakizumab in patients with Active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000018188Psoriatic ArthritisEUCTR2016-003937-62-HUSUN Pharma Global FZE360
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-002414-39-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202
已完成
2 期
A Study to Evaluate the Safety and Efficacy of Anamorelin HCL in Patients with Non Small Cell Lung CancerCTRI/2011/091/000299Helsinn Therapeutics US Inc228